SNP 6.0 array–based lesion detection and TTFT and OS in CLL (univariate analysis)
| SNP 6.0 array genomic lesions . | HR . | CI . | P . |
|---|---|---|---|
| TTFT from enrollment date | |||
| Untreated patients (N = 198) | |||
| ≥ 1 vs 0 | 1.7 | 1-2.9 | .06 |
| ≥ 2 vs ≤ 1 | 1.9 | 1.2-3.1 | .01 |
| ≥ 3 vs ≤ 2 | 3.3 | 1.9-5.5 | < .01 |
| ≥ 4 vs ≤ 3 | 4.8 | 2.6-8.8 | < .01 |
| OS from enrollment date | |||
| Untreated patients (N = 198) | |||
| ≥ 1 vs 0 | 5.5 | 1.3-24 | .01 |
| ≥ 2 vs ≤ 1 | 4.7 | 2-11.1 | < .01 |
| ≥ 3 vs ≤ 2 | 6.2 | 2.7-14.2 | < .01 |
| ≥ 4 vs ≤ 3 | 14.5 | 6.3-33.5 | < .01 |
| OS from enrollment date | |||
| Relapsed patients (N = 57) | |||
| ≥ 1 vs 0 | 1 | 0.4-2.6 | .96 |
| ≥ 2 vs ≤ 1 | 1.9 | 0.9-4.0 | .1 |
| ≥ 3 vs ≤ 2 | 2.7 | 1.2-5.7 | .01 |
| ≥ 4 vs ≤ 3 | 3.5 | 1.6-7.6 | < .01 |
| SNP 6.0 array genomic lesions . | HR . | CI . | P . |
|---|---|---|---|
| TTFT from enrollment date | |||
| Untreated patients (N = 198) | |||
| ≥ 1 vs 0 | 1.7 | 1-2.9 | .06 |
| ≥ 2 vs ≤ 1 | 1.9 | 1.2-3.1 | .01 |
| ≥ 3 vs ≤ 2 | 3.3 | 1.9-5.5 | < .01 |
| ≥ 4 vs ≤ 3 | 4.8 | 2.6-8.8 | < .01 |
| OS from enrollment date | |||
| Untreated patients (N = 198) | |||
| ≥ 1 vs 0 | 5.5 | 1.3-24 | .01 |
| ≥ 2 vs ≤ 1 | 4.7 | 2-11.1 | < .01 |
| ≥ 3 vs ≤ 2 | 6.2 | 2.7-14.2 | < .01 |
| ≥ 4 vs ≤ 3 | 14.5 | 6.3-33.5 | < .01 |
| OS from enrollment date | |||
| Relapsed patients (N = 57) | |||
| ≥ 1 vs 0 | 1 | 0.4-2.6 | .96 |
| ≥ 2 vs ≤ 1 | 1.9 | 0.9-4.0 | .1 |
| ≥ 3 vs ≤ 2 | 2.7 | 1.2-5.7 | .01 |
| ≥ 4 vs ≤ 3 | 3.5 | 1.6-7.6 | < .01 |
OS data are grouped by disease status at trial enrollment (previously untreated group and relapsed group).